Literature DB >> 10722615

Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.

D Pavliakova1, J S Moncrief, D M Lyerly, G Schiffman, D A Bryla, J B Robbins, R Schneerson.   

Abstract

Unlike the native protein, a nontoxic peptide (repeating unit of the native toxin designated rARU) from Clostridium difficile toxin A (CDTA) afforded an antigen that could be bound covalently to the surface polysaccharides of pneumococcus type 14, Shigella flexneri type 2a, and Escherichia coli K1. The yields of these polysaccharide-protein conjugates were significantly increased by prior treatment of rARU with succinic anhydride. Conjugates, prepared with rARU or succinylated (rARUsucc), were administered to mice by a clinically relevant dosage and immunization scheme. All conjugates elicited high levels of serum immunoglobulin G both to the polysaccharides and to CDTA. Conjugate-induced anti-CDTA had neutralizing activity in vitro and protected mice challenged with CDTA, similar to the rARU alone. Conjugates prepared with succinylated rARU, therefore, have potential for serving both as effective carrier proteins for polysaccharides and for preventing enteric disease caused by C. difficile.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722615      PMCID: PMC97399          DOI: 10.1128/IAI.68.4.2161-2166.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  The bacteriology of pneumococcal otitis media.

Authors:  R Austrian; V M Howie; J H Ploussard
Journal:  Johns Hopkins Med J       Date:  1977-09

2.  Structural studies on the specific type-14 pneumococcal polysaccharide.

Authors:  B Lindberg; J Lönngren; D A Powell
Journal:  Carbohydr Res       Date:  1977-09       Impact factor: 2.104

3.  The measurement of amino groups in proteins and peptides.

Authors:  R Fields
Journal:  Biochem J       Date:  1971-09       Impact factor: 3.857

4.  Increased length of hospital stay due to Clostridium difficile associated diarrhoea.

Authors:  T V Riley; J P Codde; I L Rouse
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

5.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

6.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

7.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters.

Authors:  J G Bartlett; A B Onderdonk; R L Cisneros; D L Kasper
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

8.  Structural studies of Shigella flexneri O-antigens.

Authors:  L Kenne; B Lindberg; K Petersson; E Katzenellenbogen; E Romanowska
Journal:  Eur J Biochem       Date:  1978-11-02

9.  A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques.

Authors:  G Schiffman; R M Douglas; M J Bonner; M Robbins; R Austrian
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

10.  Enzyme-linked immunosorbent assay for Clostridium difficile toxin A.

Authors:  D M Lyerly; N M Sullivan; T D Wilkins
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

View more
  9 in total

Review 1.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

2.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

3.  Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.

Authors:  Ke Jin; Shixia Wang; Chunhua Zhang; Yanling Xiao; Shan Lu; Zuhu Huang
Journal:  Hum Vaccin Immunother       Date:  2012-11-10       Impact factor: 3.452

4.  Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.

Authors:  J H Passwell; E Harlev; S Ashkenazi; C Chu; D Miron; R Ramon; N Farzan; J Shiloach; D A Bryla; F Majadly; R Roberson; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

6.  C-terminal repeats of Clostridium difficile toxin A induce production of chemokine and adhesion molecules in endothelial cells and promote migration of leukocytes.

Authors:  Chiou-Yueh Yeh; Chun-Nan Lin; Chuan-Fa Chang; Chun-Hung Lin; Huei-Ting Lien; Jen-Yang Chen; Jean-San Chia
Journal:  Infect Immun       Date:  2007-12-26       Impact factor: 3.441

7.  Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages.

Authors:  Xingmin Sun; Xiangyun He; Saul Tzipori; Ralf Gerhard; Hanping Feng
Journal:  Microb Pathog       Date:  2009-03-24       Impact factor: 3.738

8.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

Review 9.  The enterotoxicity of Clostridium difficile toxins.

Authors:  Xingmin Sun; Tor Savidge; Hanping Feng
Journal:  Toxins (Basel)       Date:  2010-07-14       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.